Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone with continental breakfast bioavailability study
NL-OMON45784Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of abiraterone in prostate cancer (PCa) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Equivalent reduced dose of abiraterone with continental breakfast. Started Oct 2016; status: active, not recruiting.
02
Drugs
abiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON45784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45784.